Author

M. A. Su

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:human· 2 Organism:mouse· 2 Approach:statistical model· 2 Assay:ATAC-seq· 1 Assay:bulk RNA-seq· 1

Frequent Co-Authors

A. Drakaki· 2 shared A. Ribas· 2 shared A. T. Hoang· 2 shared A. Y. Patel· 2 shared H.-C. Chen· 2 shared M. G. Lechner· 2 shared M. I. Cheng· 2 shared P. Famini· 2 shared

Activity by Year

2022-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Drakaki

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Clonally-Expanded, Thyrotoxic Autoimmune Mediator CD8+ T cells Driven by IL21 Contribute to Checkpoint Inhibitor Thyroiditis

M. G. Lechner, Z. Zhou, A. T. Hoang, N. Huang, J. Ortega, L. N. Scott, H.-C. Chen, A. Y. Patel, R. Y. Tafti, K. Kim, W. Hugo, P. Famini, A. Drakaki, A. Ribas, T. E. Angell, M. A. Su

The paper identifies clonally expanded CD8+ T cells driven by IL21 in ICI-thyroiditis using scRNA-seq and validates their role in thyroid inflammation.

bioRxiv · Dec 18, 2022 · PreprintImmunology

Sex differences in NK cells mediated by the X-linked epigenetic regulator UTX

M. I. Cheng, L. Riggan, J. H. Li, R. Y. Tafti, S. Chin, F. Ma, M. Pellegrini, H. Hrncir, A. P. Arnold, T. E. O'Sullivan, M. A. Su

This study identifies UTX as a key X-linked epigenetic regulator causing sex differences in NK cell function, with males showing reduced IFN-γ production despite higher numbers.

bioRxiv · Apr 21, 2022 · PreprintImmunology

Inhibition of the IL-17A axis Protects against Immune-related Adverse Events while Supporting Checkpoint Inhibitor Anti-tumor Efficacy

M. G. Lechner, A. Y. Patel, W. Hugo, T. E. Angell, M. I. Cheng, M. S. Pioso, A. T. Hoang, N. Yakobian, E. C. McCarthy, H.-C. Chen, E. D. Rodriguez, L. Guo, M. Astourian, A. Drakaki, P. Famini, , M. A. Su

This study shows that inhibiting the IL-17A axis reduces immune-related adverse events in checkpoint inhibitor-treated mice without affecting anti-tumor efficacy.

bioRxiv · Jan 19, 2022Immunology